GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (OTCPK:ROQAF) » Definitions » Additional Paid-In Capital

ROQAF (Roquefort Therapeutics) Additional Paid-In Capital : $5.84 Mil(As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Roquefort Therapeutics Additional Paid-In Capital?


Roquefort Therapeutics's quarterly additional paid-in capital increased from Dec. 2023 ($5.57 Mil) to Jun. 2024 ($5.60 Mil) and increased from Jun. 2024 ($5.60 Mil) to Dec. 2024 ($5.84 Mil).

Roquefort Therapeutics's annual additional paid-in capital increased from Dec. 2022 ($5.36 Mil) to Dec. 2023 ($5.57 Mil) and increased from Dec. 2023 ($5.57 Mil) to Dec. 2024 ($5.84 Mil).


Roquefort Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Roquefort Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Additional Paid-In Capital Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
4.60 5.36 5.57 5.84

Roquefort Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Additional Paid-In Capital Get a 7-Day Free Trial 5.36 5.56 5.57 5.60 5.84

Roquefort Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Roquefort Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Roquefort Therapeutics Business Description

Traded in Other Exchanges
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines